Pharmaceutical Executive
To educate anesthesiologists that post-operative nausea and vomiting (PONV) is "no fun for anyone," GSW Worldwide created WoozyWorld.com, a "non-amusement" that highlights the need for MGI Pharma's 72-hour antiemetic Aloxi.
WOOZYWORLD
GSW Worldwide
BRAND Market education for PONV CLIENT MGI Pharma/Eisai FROM LEFT: (Seated): Sean Cowan, creative director, digital wave; Kristan Early, vice president, creative director; (Standing): Dean Tepper, senior vice president, group creative director; Seth Quillin, senior vice president, digital operations
To educate anesthesiologists that post-operative nausea and vomiting (PONV) is "no fun for anyone," GSW Worldwide created WoozyWorld.com, a "non-amusement" that highlights the need for MGI Pharma's 72-hour antiemetic Aloxi. The team unveiled the unmistakable (yet unbranded) site before the drug's March 2008 launch. "Creatively, we gave WoozyWorld a darker, tongue-in-cheek edge," says Sean Cowan, creative director, digital wave. They drew inspiration from the retail industry—which is more forward-looking than the pharmaceutical space—to create great, engaging content.
WoozyWorld includes information on the very real consequences of patients' post-operative side effects—with the goal to "make [anesthesiologists] care a little bit longer." "When patients undergo anesthesia, all anesthesiologists really care about is the first 24 hours after surgery," says Kristan Early, vice president, creative director. "Once patients are discharged, anesthesiologists feel their job is done. But in reality, a patient can still become sick once they arrive home or even days later."
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.